DAAO Inhibitors for the treatment of Schizophrenia

DAAO 抑制剂治疗精神分裂症

• 批准号: 8247004
• 负责人: Takashi Tsukamoto
• 金额: $ 58.52万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-03-24 至 2014-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8247004
• 关键词: Agonist; Animal Model; Antipsychotic Agents; Attenuated; Behavioral; Benchmarking; Bicyclo Compounds; Biochemical Reaction; Biological Availability; Brain; C57BL/6 Mouse; Chronic; Clinical; Clinical Data; Clinical Research; Cognitive deficits; Coupled; D-Amino Acid Dehydrogenase; Data; Development; Dose; Drug Delivery Systems; Drug Kinetics; Enzymes; Exhibits; Face; Faculty; Generations; Genetic; Genetic Models; Genetically Engineered Mouse; Glycine; Goals; Human; Hydrogen Peroxide; Impaired cognition; In Vitro; Inhibitory Concentration 50; Institutes; Kidney; Lead; Liver; Measures; Mediating; Metabolic; Metabolism; Methods; Mus; N-Methyl-D-Aspartate Receptors; Neurobehavioral Manifestations; Oral; Patients; Peripheral; Pharmaceutical Preparations; Phencyclidine; Plasma; Positioning Attribute; PrP; Pre-Clinical Model; Psychiatry; Recombinants; Reporting; Research; Research Project Grants; Research Proposals; Safety; Schizophrenia; Science; Screening procedure; Series; Serine; Site; Solid; Structure-Activity Relationship; Symptoms; Testing; Therapeutic; Toxic effect; Translating; analog; azastene; base; dosage; drug candidate; drug discovery; endophenotype; improved; in vivo; in vivo Model; inhibitor/antagonist; innovation; medical schools; meetings; mouse model; nephrotoxicity; neuropsychiatry; neurotransmission; novel; novel therapeutics; pre-clinical; prepulse inhibition; prevent; programs; prototype; public health relevance; response; scale up

DESCRIPTION (provided by applicant): Cumulative evidence suggests that allosteric activation of the NMDA receptor through the glycine modulatory site provides new therapeutic potential for the treatment of schizophrenia. D-Serine, an endogenous agonist at the glycine modulatory site, has been shown to be effective at treating positive, negative, and cognitive symptoms of schizophrenia in clinical studies. Despite the highly encouraging clinical data, clinical development of D-serine will likely face obstacles because of the high dosages required for efficacy (approximately 2 grams per day). This is primarily due to the substantial metabolism of peripherally administered D-serine by D-amino acid oxidase (DAAO), a flavoenzyme expressed in the liver, kidneys, and brain. DAAO-mediated metabolism of D-serine not only limits D-serine bioavailability but also has the potential to induce kidney toxicity through the generation of hydrogen peroxide. Therefore, we hypothesize that blockade of DAAO-mediated D-serine metabolism could substantially lower the dosages required for efficacy while preventing hydrogen peroxide-induced peripheral toxicity. To this end, we found that co-administration of D-serine and a DAAO inhibitor significantly increases plasma and brain levels of D-serine and enhances in vivo potency of D-serine in an animal model of schizophrenia. The goal of the proposed research is to translate our findings into innovative therapeutics by conducting a strategic research plan that consists of the following: (Aim 1) Perform lead optimization studies on benzoisoxazole derivatives and other classes of fused bicyclic compounds to establish SAR (structure-activity relationships) and identify potent, selective, non-toxic, and metabolically stable drug-like DAAO inhibitors; (Aim 2) Assess the effects on D-serine oral bioavailability of potent drug-like DAAO inhibitors identified in Aim 1; (Aim 3) Assess the effect of DAAO inhibitors identified in Aim 2 on D-serine's ability to attenuate phencyclidine (PCP) induced prepulse inhibition (PPI) deficits in mice; (Aim 4) Assess the effects of DAAO inhibitors identified in Aim 3 on D-serine's ability to attenuate PPI deficits in a genetic mouse model of schizophrenia. Upon completion of this project, we expect to identify preclinical candidate DAAO inhibitors that could lead to a truly novel antipsychotic drug for the treatment of schizophrenia. PUBLIC HEALTH RELEVANCE: The goal of the proposed research project is to perform highly focused drug discovery research and identify potent drug-like D-amino acid oxidase (DAAO) inhibitors to be administered in combination with D-serine to facilitate allosteric activation of the NMDA receptor-mediated neurotransmission. Preclinical candidates identified from this project will have the potential to serve as truly novel antipsychotic drugs for schizophrenia patients, particularly those suffering from negative symptoms and cognitive impairments.

描述（由申请人提供）：累积的证据表明，通过甘氨酸调节位点对NMDA受体的变构激活为精神分裂症的治疗提供了新的治疗潜力。D-丝氨酸是甘氨酸调节位点的内源性激动剂，在临床研究中已被证明可有效治疗精神分裂症的阳性、阴性和认知症状。尽管有非常令人鼓舞的临床数据，但D-丝氨酸的临床开发可能会面临障碍，因为有效性所需的剂量很高（每天约2克）。这主要是由于D-氨基酸氧化酶（DAAO）（一种在肝脏、肾脏和大脑中表达的黄素酶）对外周给药的D-丝氨酸进行了大量代谢。DAAO介导的D-丝氨酸代谢不仅限制了D-丝氨酸的生物利用度，而且还可能通过产生过氧化氢诱导肾毒性。因此，我们假设阻断DAAO介导的D-丝氨酸代谢可以显著降低疗效所需的剂量，同时防止过氧化氢诱导的外周毒性。为此，我们发现在精神分裂症动物模型中，D-丝氨酸和DAAO抑制剂的联合给药显着增加了D-丝氨酸的血浆和脑水平，并增强了D-丝氨酸的体内效力。拟议研究的目标是通过实施战略研究计划将我们的发现转化为创新疗法，该计划包括以下内容：（目的1）对苯并异恶唑衍生物和其他类别的稠合双环化合物进行先导优化研究，以建立SAR（结构-活性关系）并鉴定有效的、选择性的、无毒的和代谢稳定的药物样DAAO抑制剂;（目的3）评估目的2中鉴定的DAAO抑制剂对D-丝氨酸减弱小鼠中苯环利定（PCP）诱导的前脉冲抑制（PPI）缺陷的能力的影响;（目的4）评估目的3中鉴定的DAAO抑制剂对D-丝氨酸减弱精神分裂症遗传小鼠模型中PPI缺陷的能力的影响。在这个项目完成后，我们希望确定临床前候选DAAO抑制剂，可能导致一个真正的新型抗精神病药物治疗精神分裂症。 公共卫生关系：拟议的研究项目的目标是进行高度集中的药物发现研究，并确定有效的药物样D-氨基酸氧化酶（DAAO）抑制剂与D-丝氨酸联合给药，以促进NMDA受体介导的神经传递的变构激活。从该项目中确定的临床前候选药物将有可能成为精神分裂症患者的真正新型抗精神病药物，特别是那些患有阴性症状和认知障碍的患者。